ViroVet Overview

  • Founded
  • 2015
  • Status
  • Private
  • Employees
  • 4
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $6.7M
Latest Deal Amount
  • Investors
  • 10

ViroVet General Information


Developer of antiviral drugs intended to control the spread of viral diseases in livestock. The company's antiviral drugs are for respiratory disease complexes and is an innovative vaccines for viral infections in swine leading the pipeline, enabling livestock producers, national governments and international organizations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Ambachtenlaan 1
  • 3001 Leuven
  • Belgium

ViroVet Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ViroVet Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 04-Jun-2020 $6.7M 000.00 Completed Generating Revenue
3. Grant 19-Sep-2018 00000 000.00 Completed Generating Revenue
2. Early Stage VC 28-Aug-2018 $3.46M $11.2M 00.00 Completed Generating Revenue
1. Early Stage VC (Series A) 09-Oct-2017 $7.7M $7.7M Completed Generating Revenue

ViroVet Cap Table

To view ViroVet‘s complete cap table, request access »
Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred A 000,000 000.00 000.00 00 000.00 00.000
Ordinary A 00,000 000.00 000.00 00 000.00 00.000

ViroVet Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
000000 00000000 Angel-Backed Durham, NC 00 000.00 0000000000 000.00

ViroVet Executive Team (4)

Name Title Board Seat Contact Info
Erwin Blomsma Ph.D Co-Founder, Chief Executive Officer & Board Member
Stefaan Wera Co-Founder & Chief Operating Officer
Nesya Goris Ph.D Co-Founder & Chief Development Officer
Johan Neyts Ph.D Chief Scientific Officer

ViroVet Board Members (7)

To view ViroVet‘s full board member team, request access »
Name Representing Role Since
David Devigne Ph.D Self Board Member 000 0000
Erwin Blomsma Ph.D ViroVet Co-Founder, Chief Executive Officer & Board Member 000 0000
Filip Goossens Ph.D ViroVet Board Member 000 0000
George Gunn Ph.D Self Chairman 000 0000
Luc Basstanie Self Board Member 000 0000

ViroVet Investors (10)

To view ViroVet‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seventure Partners Venture Capital Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Vlaams Agentschap Innoveren en Ondernemen Endowment Limited Partner 000 0000 000000 0
Agri Investment Fund PE/Buyout Minority 000 0000 000000 0
Aratana Therapeutics Corporation Minority 000 0000 000000 0

Ready to get started?

Request a free trial